Lisata Therapeutics (LSTA) News Today $2.71 +0.19 (+7.54%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Lisata Therapeutics complete enrollment in CENDIFOX trialDecember 11, 2024 | markets.businessinsider.comLisata Therapeutics Completes Enrollment for Cancer Therapy TrialDecember 11, 2024 | finance.yahoo.comLisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipDecember 11, 2024 | proactiveinvestors.comLisata Therapeutics completes patient enrollment for CENDIFOX trialDecember 10, 2024 | proactiveinvestors.comLisata Therapeutics Announces Completion of Enrollment in the CENDIFOX TrialDecember 10, 2024 | globenewswire.comLisata and Kuva Labs partner for MR imaging agents to detect cancerDecember 6, 2024 | msn.comLisata Therapeutics, Kuva Labs enter license agreementDecember 4, 2024 | markets.businessinsider.comLisata Therapeutics and Kuva Labs to collaborate on cancer imaging solutionDecember 3, 2024 | proactiveinvestors.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year'November 21, 2024 | stockhouse.comLisata Therapeutics: Strong Financials and Diverse Clinical Progress Bolster Buy RatingNovember 21, 2024 | markets.businessinsider.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’November 19, 2024 | markets.businessinsider.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19, 2024 | proactiveinvestors.comLisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsNovember 19, 2024 | proactiveinvestors.comLisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'November 19, 2024 | globenewswire.comLisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMINovember 16, 2024 | proactiveinvestors.comLisata Therapeutics Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comLisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ...November 13, 2024 | finance.yahoo.comLisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings Outlook For Lisata TherapeuticsNovember 12, 2024 | benzinga.comLisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025November 12, 2024 | proactiveinvestors.comLisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comLisata Therapeutics, Valo Therapeutics enter preclinical research collaborationNovember 7, 2024 | markets.businessinsider.comLisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapyNovember 6, 2024 | proactiveinvestors.comLisata Therapeutics and Valo Therapeutics Announce Preclinical Research CollaborationNovember 6, 2024 | globenewswire.comLisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024November 6, 2024 | globenewswire.comLisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMINovember 2, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor EventsOctober 31, 2024 | globenewswire.comLisata Therapeutics entered research agreement with University of CincinnatiOctober 28, 2024 | markets.businessinsider.comLisata Therapeutics strikes research partnership to investigate new treatment for endometriosisOctober 28, 2024 | proactiveinvestors.comLisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of EndometriosisOctober 28, 2024 | globenewswire.comRAPT Therapeutics (NASDAQ:RAPT) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comLisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsOctober 3, 2024 | finance.yahoo.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comStrong Buy Rating for Lisata Therapeutics Backed by Promising Certepetide Clinical PerformanceSeptember 19, 2024 | markets.businessinsider.comLisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialSeptember 17, 2024 | finance.yahoo.comLisata Therapeutics begins treating second cohort of patients in bile duct cancer trialSeptember 17, 2024 | proactiveinvestors.comLisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsSeptember 9, 2024 | globenewswire.comLisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | finance.yahoo.comLisata Therapeutics' certepetide receives Orphan Drug Designation for cholangiocarcinomaSeptember 5, 2024 | proactiveinvestors.comLisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaSeptember 5, 2024 | globenewswire.comWill Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely?August 22, 2024 | finance.yahoo.comLisata Therapeutics: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 13, 2024 | markets.businessinsider.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.comLSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024August 12, 2024 | investorplace.comLisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 12, 2024 | markets.businessinsider.comLisata Therapeutics coming off strong 2Q performance, CEO saysAugust 12, 2024 | proactiveinvestors.comLisata Therapeutics CMO details pancreatic cancer research collaboration with Haystack Oncology - ICYMIJuly 27, 2024 | proactiveinvestors.comLisata Therapeutics (NASDAQ:LSTA) Stock Quotes, Forecast and News SummaryJuly 22, 2024 | benzinga.comHaystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer TherapyJuly 19, 2024 | markets.businessinsider.comHaystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer TherapyJuly 19, 2024 | finance.yahoo.com Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address This Indicator called BOTH NVDA rallies (Ad)Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. LSTA Media Mentions By Week LSTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LSTA News Sentiment▼0.000.59▲Average Medical News Sentiment LSTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LSTA Articles This Week▼02▲LSTA Articles Average Week Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PowerUp Acquisition News Today 23andMe News Today CytomX Therapeutics News Today Adlai Nortye News Today Karyopharm Therapeutics News Today Reviva Pharmaceuticals News Today Quince Therapeutics News Today ALX Oncology News Today PMV Pharmaceuticals News Today Genelux News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LSTA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
